Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Oct;119(7):840-846.
doi: 10.1038/s41416-018-0266-8. Epub 2018 Oct 8.

A minority-group of renal cell cancer patients with high infiltration of CD20+B-cells is associated with poor prognosis

Affiliations

A minority-group of renal cell cancer patients with high infiltration of CD20+B-cells is associated with poor prognosis

Elin Sjöberg et al. Br J Cancer. 2018 Oct.

Abstract

Background: The role of B-lymphocytes in solid tumours is unclear. Tumour biology studies have implied both anti- and pro-tumoural effects and prognostic studies have mainly linked B-cells to increased survival. This study aimed to analyse the clinical relevance of B-lymphocytes in renal cell cancer (RCC), where information on the prognostic impact is lacking.

Methods: Following immunohistochemistry (IHC) stainings with a CD20 antibody, density of CD20+ B-cells was quantified in an RCC discovery- and validation cohort. Associations of B-cell infiltration, determined by CD20 expression or a B-cell gene-signature, and survival was also analysed in 14 publicly available gene expression datasets of cancer, including the kidney clear cell carcinoma (KIRC) dataset.

Results: IHC analyses of the discovery cohort identified a previously unrecognised subgroup of RCC patients with high infiltration of CD20+ B-cells. The B-cell-high subgroup displayed significantly shorter survival according to uni- and multi-variable analyses. The association between poor prognosis and high density of CD20+ B-cells was confirmed in the validation cohort. Analyses of the KIRC gene expression dataset using the B-cell signature confirmed findings from IHC analyses. Analyses of other gene expression datasets, representing 13 different tumour types, indicated that the poor survival-association of B-cells occurred selectively in RCC.

Conclusion: This exploratory study identifies a previously unrecognised poor-prognosis subset of RCC with high density of CD20-defined B-cells.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Variable infiltration of CD20+ cells in RCC. Immunohistochemistry staining with CD20 antibodies was used to identify tumour infiltrating B-lymphocytes in RCC patients. The majority of patients displayed no (left panel) or low infiltration (middle panel), whereas a minority of cases demonstrated high infiltration of CD20+ cells (right panel). Scale bar 100 μm
Fig. 2
Fig. 2
Correlation of CD20 status and prognosis of RCC patients in two independent cohorts. Kaplan–Meier curves showing the overall survival of RCC patients with low or high infiltration of CD20+ cells in the discovery cohort (left panel) and the validation cohort (right panel)
Fig. 3
Fig. 3
Associations between survival and a B-lymphocyte signature or MS4A1 expression in gene expression datasets of different tumour types. a Kaplan–Meier plot showing overall survival of clear cell RCC patients in the KIRC gene expression dataset (TCGA) with low or high B-lymphocyte gene signature score (MS4A1/CD19/PAX5). b Association of MS4A1 expression and overall survival in 14 cancer gene expression datasets from the TCGA database

Similar articles

Cited by

References

    1. Hsieh JJ, et al. Renal cell carcinoma. Nat. Rev. Dis. Primers. 2017;3:17009. doi: 10.1038/nrdp.2017.9. - DOI - PMC - PubMed
    1. Ghatalia P, Zibelman M, Geynisman DM, Plimack ER. Checkpoint inhibitors for the treatment of renal cell carcinoma. Curr. Treat. Options Oncol. 2017;18:7. doi: 10.1007/s11864-017-0458-0. - DOI - PubMed
    1. Harlander S, et al. Combined mutation in Vhl, Trp53 and Rb1 causes clear cell renal cell carcinoma in mice. Nat. Med. 2017;23:869–877. doi: 10.1038/nm.4343. - DOI - PMC - PubMed
    1. Choueiri TK, Motzer RJ. Systemic therapy for metastatic renal-cell carcinoma. N. Eng. J. Med. 2017;376:354–366. doi: 10.1056/NEJMra1601333. - DOI - PubMed
    1. Choueiri TK, et al. Cabozantinib versus everolimus in advanced renal-cell carcinoma. N. Eng. J. Med. 2015;373:1814–1823. doi: 10.1056/NEJMoa1510016. - DOI - PMC - PubMed

Publication types

MeSH terms